0 оценок0% нашли этот документ полезным (0 голосов)
147 просмотров22 страницы
TL Hines writes "Noir Bizarre" stories, winning recognitions such as the "25 Best Genre Novels of the Year" award from Library Journal. But in 2007, he became the main character in his strangest tale yet: a follicular Non-Hodgkins Lymphoma diagnosis. After months of research and appointments, he received Bexxar radioimmunotherapy and is now cancer-free---even though Bexxar isn't FDA approved for first-line treatment. This presentation, given at the 2009 Montana State Radiological Tech Conference, offers a patient perspective on cancer diagnosis and treatment.
TL Hines writes "Noir Bizarre" stories, winning recognitions such as the "25 Best Genre Novels of the Year" award from Library Journal. But in 2007, he became the main character in his strangest tale yet: a follicular Non-Hodgkins Lymphoma diagnosis. After months of research and appointments, he received Bexxar radioimmunotherapy and is now cancer-free---even though Bexxar isn't FDA approved for first-line treatment. This presentation, given at the 2009 Montana State Radiological Tech Conference, offers a patient perspective on cancer diagnosis and treatment.
Авторское право:
Attribution Non-Commercial (BY-NC)
Доступные форматы
Скачайте в формате PDF, TXT или читайте онлайн в Scribd
TL Hines writes "Noir Bizarre" stories, winning recognitions such as the "25 Best Genre Novels of the Year" award from Library Journal. But in 2007, he became the main character in his strangest tale yet: a follicular Non-Hodgkins Lymphoma diagnosis. After months of research and appointments, he received Bexxar radioimmunotherapy and is now cancer-free---even though Bexxar isn't FDA approved for first-line treatment. This presentation, given at the 2009 Montana State Radiological Tech Conference, offers a patient perspective on cancer diagnosis and treatment.
Авторское право:
Attribution Non-Commercial (BY-NC)
Доступные форматы
Скачайте в формате PDF, TXT или читайте онлайн в Scribd
helped me through a cancer diagnosis •••••••••••••••••••• TL HINES | APRIL 18, 2009 LIFE IN B.C. TIMES (BEFORE CANCER) LIFE IN B.C. TIMES (BEFORE CANCER) LIFE IN A.D. TIMES (AFTER DIAGNOSIS) LIFE IN A.D. TIMES (AFTER DIAGNOSIS) • Stage 4 Follicular NHL: about 5% bone marrow involvement. • Considered “incurable.” • Median Survival: ~10 years. • Scary. But…I didn’t understand the data. (More on that later.) BLAME (OR THANK) THE LIVER THE LYMPHOMA TOUR • Scans, biopsies and tests. Oh, my. • Web research: Do NOT Google “lymphoma survival rates.” • Five oncologists. Five opinions. TREATMENT OPTIONS? YES. ERR…NO. • Chemo: R-CHOP, R-CVP, Fludarabine. • Single-agent rituximab. • Radioimmunotherapy. • Watch & Wait (Watch & Worry). • Clinical trials: new agents, vaccines. • Big question: Treat now, or treat later? FIRST-LINE BEXXAR TRIAL • 76 FNHL patients (Stages 3 & 4). • Overall response: 95%. • Complete response: 75%. • Median PFS for CR: 9.2 years. • Only three relapses after 8 years. DANGER, WILL ROBINSON • MDS, AML. • Hypothyroidism. • Not much long-term data. • Oh, and the little matter of Bexxar not being FDA-approved for first-line treatment. I CHOOSE YOU, BEXXAR • Rationale: Tolerability, ease of treatment, trial data, family considerations, ability to be my own night light after radioactive dose. • Clinical trial? Bzzzt. • Tony becomes a defense attorney: might this have curative potential? BEXXAR, OR BEXXAREN’T? • Work with Billings Clinic and BC/BS on approval. • Wait a minute: you need that high- energy columnator. • Maybe just go with Zevalin vs. Bexxar? • Community Medical Center in Missoula to the rescue. BEXXAR BOY’S UNIFORM BEXXAR BOY IS BORN BEXXAR BOY IS BORN BEXXAR BOY IS BORN THE CONTINUING ADVENTURE • Complete response in three months (Faster than expected) • Continued NED scans July 08, Jan 09 • Only real side effect: hypothyroidism (treated with syntheroid) CURED BY CANCER? • In many ways, the cancer journey has made me a better person. • Value of relationships; thankful for what you have; let the little stuff go. • Lost 40 pounds (so far), running 20+ miles a week; training for a half- marathon. Would I be otherwise? WHAT I LEARNED • Danger of statistics: survival, cure, etc. • When you hear “no,” go to plan B. Or C. • Different strokes for different folks. • Healthcare decisions are business partnerships: choose partners wisely. • When you hear “no,” go to plan D. Or E. • Make a choice: find the positive. WHAT I LEARNED: THE SEQUEL • We need to encourage physicians to recommend clinical trials. • Patients need to be more active, rather than passive, in their health care. • Our health care system is neither perfect, nor perfectly awful. MORE BEXXAR BOYS AND GIRLS NEEDED • Bexxar/Zevalin are underused. Why? – Oncology/radiology handoff. – CMS reimbursement issues. – Misconceptions: cost, marrow damage, secondary cancers. • So: Make friends with oncologists. Tell them you love them and want to help. THANK YOU. THANK YOU VERY MUCH. • More than you ever wanted to know: www.tlhines.com/lymphoma